Keybank National Association OH Cuts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Keybank National Association OH cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,140,610 shares of the company's stock after selling 33,978 shares during the period. Johnson & Johnson comprises approximately 0.8% of Keybank National Association OH's investment portfolio, making the stock its 25th largest holding. Keybank National Association OH's holdings in Johnson & Johnson were worth $189,159,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of JNJ. Brighton Jones LLC raised its position in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. Hudson Value Partners LLC raised its position in Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the period. Bedel Financial Consulting Inc. raised its position in Johnson & Johnson by 7.0% in the fourth quarter. Bedel Financial Consulting Inc. now owns 14,878 shares of the company's stock worth $2,301,000 after acquiring an additional 973 shares during the period. Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 3.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 18,187,082 shares of the company's stock worth $2,630,216,000 after acquiring an additional 547,714 shares during the period. Finally, Bahl & Gaynor Inc. raised its position in Johnson & Johnson by 303.0% in the fourth quarter. Bahl & Gaynor Inc. now owns 1,328,414 shares of the company's stock worth $192,115,000 after acquiring an additional 998,761 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ stock traded up $0.34 during mid-day trading on Friday, reaching $155.90. 3,482,521 shares of the company traded hands, compared to its average volume of 8,059,757. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The company has a market capitalization of $375.11 billion, a P/E ratio of 17.34, a P/E/G ratio of 2.36 and a beta of 0.41. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a fifty day moving average price of $153.68 and a 200-day moving average price of $154.09.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.34%. Johnson & Johnson's payout ratio is presently 57.84%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on JNJ shares. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Royal Bank Of Canada reissued an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Raymond James Financial decreased their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Bank of America decreased their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.